Oakrum Pharma and Aucta Pharmaceuticals have received the Food and Drug Administration’s green light for a generic version of Novartis’ Jadenu Sprinkle (deferasirox granules) in dosage strengths of 90 ...

The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle ...

The FDA announced the approval of Jadenu tablets for the treatment of certain patients with chronic iron overload, according to a press release from the drug’s manufacturer. Jadenu (deferasirox, ...

Basel, March 30, 2015 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu TM (deferasirox) tablets, a new oral formulation of Exjade ® (deferasirox) tablets ...

Novartis AG NVS announced that the FDA has approved Jadenu (deferasirox) tablets, a new oral formulation of Exjade tablets, for the treatment of chronic iron overload due to blood transfusions in ...

Both the tablets and granules should not be taken with aluminum-containing antacid products. The drug labeling contains additional information for patients who are on current chelation therapy with ...

JADENU or JADENU SPRINKLE can cause acute renal failure and death... Evaluate baseline renal function prior to starting or increasing Jadenu or Jadenu Sprinkle dosing in all patients. JADENU or JADENU ...

DORVAL, QC, May 6, 2016 /CNW/ - Canadians requiring treatment for chronic iron overload have a new treatment option with the availability of JADENU™ (deferasirox) following its recent approval by ...

To simplify treatment administration for patients with chronic iron overload Novartis announced that the US Food and Drug Administration (FDA) has approved Jadenu (deferasirox) tablets, a new oral ...

Marketing AstraZeneca rolls out Movantik; Novartis nabs FDA blessing for Jadenu; Indian drugmakers start hiring pharmacy grads as sales reps; By Tracy Staton Apr 1, 2015 9:42am Marketing ...

Chronic iron overload is a serious condition that can affect people with sickle cell disease, thalassemia and myelodysplastic syndromes Basel, March 30, 2015 - Novartis announced today that the US ...